.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has opted for Eli Lilly (NYSE: LLY) as its best biopharma pick for 2025 as well as rated one more 9 labels in the room as obese. The assets bank pointed out in a keep in mind that it continues to believe “diabesity is set to become.